Enochian Biosciences Inc. announced that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (UCLA). The experiments demonstrated highly significant reductions in the weight and volume of pancreatic tumors following therapy with the Company's proprietary technology combining cell-, gene- and immunotherapy. Those results correlated with strong immune responses, indicating proof-of-concept of the way the technology was intended to act.

The results were part of an invited plenary lecture delivered by Dr. Jewett at the 8th Annual Innate Killer Summit in San Diego, California (relevant slides from the presentation can be viewed at: Presentation Excerpt--Innate Killer Summit_ENOB DC-11). The humanized mouse model is widely used to study cancer therapies that could potentially be applicable to human disease.